08:00 , Nov 25, 2002 |  BC Week In Review  |  Clinical News

Herpes vaccine: Phase I/II

In a Mexican Phase I/II trial in 62 patients, one-year follow-up data showed the vaccine prevented all signs and symptoms of recurrent genital herpes in 43.5% of patients for 12-15 months. One-year data on the...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Clinical News

Herpes vaccine: Phase I/II

Researchers published in Cutis results from an ongoing Mexican Phase I/II trial in 32 patients that showed those receiving the vaccine had 3-fold less herpes episodes versus the prior year (p<0.001). HSV-2 episodes were completely...
07:00 , May 1, 2000 |  BC Week In Review  |  Clinical News

HSV-2 theracine: Began Phase I/II trial

AuRx Inc., Baltimore, Md.   Product: HSV-2 theracine   Business: Infectious diseases   Therapeutic category: Immune stimulation, Viral replication   Target: Immune cells   Description: Live recombinant herpes virus vaccine   Indication: Prevent recurrences of...
07:00 , Apr 28, 2000 |  BC Extra  |  Clinical News

AuRx to begin a Phase I/II in Mexico

AuRx (Baltimore, Md.) will begin a 64-patient Phase I/II trial of its HSV-2 recombinant herpes theracine in mid-May. The theracine is being developed to prevent recurrences of genital herpes....